JP2022527373A5 - - Google Patents
Info
- Publication number
- JP2022527373A5 JP2022527373A5 JP2021559435A JP2021559435A JP2022527373A5 JP 2022527373 A5 JP2022527373 A5 JP 2022527373A5 JP 2021559435 A JP2021559435 A JP 2021559435A JP 2021559435 A JP2021559435 A JP 2021559435A JP 2022527373 A5 JP2022527373 A5 JP 2022527373A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence described
- lcdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024002528A JP7688175B2 (ja) | 2019-04-10 | 2024-01-11 | Retを結合するヒト抗体およびその使用方法 |
| JP2025085725A JP7904951B2 (ja) | 2019-04-10 | 2025-05-22 | Retを結合するヒト抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832218P | 2019-04-10 | 2019-04-10 | |
| US62/832,218 | 2019-04-10 | ||
| PCT/US2020/027554 WO2020210551A1 (en) | 2019-04-10 | 2020-04-09 | Human antibodies that bind ret and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002528A Division JP7688175B2 (ja) | 2019-04-10 | 2024-01-11 | Retを結合するヒト抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527373A JP2022527373A (ja) | 2022-06-01 |
| JP2022527373A5 true JP2022527373A5 (cg-RX-API-DMAC7.html) | 2023-01-10 |
| JP7511576B2 JP7511576B2 (ja) | 2024-07-05 |
Family
ID=70554175
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559435A Active JP7511576B2 (ja) | 2019-04-10 | 2020-04-09 | Retを結合するヒト抗体およびその使用方法 |
| JP2024002528A Active JP7688175B2 (ja) | 2019-04-10 | 2024-01-11 | Retを結合するヒト抗体およびその使用方法 |
| JP2025085725A Active JP7904951B2 (ja) | 2019-04-10 | 2025-05-22 | Retを結合するヒト抗体およびその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024002528A Active JP7688175B2 (ja) | 2019-04-10 | 2024-01-11 | Retを結合するヒト抗体およびその使用方法 |
| JP2025085725A Active JP7904951B2 (ja) | 2019-04-10 | 2025-05-22 | Retを結合するヒト抗体およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220185900A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3953390A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7511576B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102967743B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113993898B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020270966B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3134258A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL287067A (cg-RX-API-DMAC7.html) |
| MA (1) | MA55615A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021012335A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020210551A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4277904A1 (en) | 2021-01-15 | 2023-11-22 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
| MX2023009113A (es) | 2021-02-03 | 2023-08-10 | Seagen Inc | Conjugados y compuestos inmunoestimulantes. |
| WO2023144790A1 (en) * | 2022-01-31 | 2023-08-03 | Glaxosmithkline Intellectual Property (No.3) Limited | Prevention and treatment of headaches |
| EP4518905A1 (en) | 2022-05-06 | 2025-03-12 | Seagen Inc. | Immunomodulatory antibody-drug conjugates |
| IL318450A (en) | 2022-08-03 | 2025-03-01 | Seagen Inc | Immunostimulatory ANTI-PD-L1-Drug conjugates |
| EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
| AU2024403267A1 (en) * | 2023-12-20 | 2026-07-16 | Dianthus Therapeutics Opco, Inc. | Pharmaceutical compositions comprising antibodies for treatment of c1s mediated disorders and methods of using the same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6677135B1 (en) | 1996-05-08 | 2004-01-13 | Biogen, Inc. | Ret ligand (RetL) for stimulating neutral and renal growth |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| JP2008546716A (ja) * | 2005-06-17 | 2008-12-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗GFRα3抗体 |
| JPWO2007049624A1 (ja) * | 2005-10-24 | 2009-04-30 | 武田薬品工業株式会社 | 癌の予防・治療剤 |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| ES2701649T3 (es) | 2009-01-14 | 2019-02-25 | Ablynx Nv | Administración pulmonar de dominios variables individuales de inmunoglobulina y constructos de los mismos |
| CN102459332B (zh) | 2009-06-05 | 2015-08-19 | 埃博灵克斯股份有限公司 | 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体 |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| JO3462B1 (ar) * | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
| KR102288722B1 (ko) * | 2013-08-30 | 2021-08-12 | 모멘티브 퍼포먼스 머티리얼즈 인크. | 아미노산을 갖는 수분 경화성 화합물 |
| GB201512215D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| AU2016332900C1 (en) | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| KR101859576B1 (ko) * | 2016-06-30 | 2018-05-18 | 가톨릭대학교 산학협력단 | Kif5b-ret 융합 단백질을 특이적으로 검출하는 항체 및 이의 용도 |
| KR20200059243A (ko) | 2017-09-20 | 2020-05-28 | 리제너론 파마슈티칼스 인코포레이티드 | 패신저 유전자 돌연변이 부담이 높은 종양을 가진 환자에 대한 면역 치료요법 |
-
2020
- 2020-04-09 MX MX2021012335A patent/MX2021012335A/es unknown
- 2020-04-09 AU AU2020270966A patent/AU2020270966B2/en active Active
- 2020-04-09 WO PCT/US2020/027554 patent/WO2020210551A1/en not_active Ceased
- 2020-04-09 KR KR1020217036432A patent/KR102967743B1/ko active Active
- 2020-04-09 CA CA3134258A patent/CA3134258A1/en active Pending
- 2020-04-09 US US17/602,562 patent/US20220185900A1/en active Pending
- 2020-04-09 EP EP20724257.9A patent/EP3953390A1/en active Pending
- 2020-04-09 KR KR1020267015613A patent/KR20260079447A/ko active Pending
- 2020-04-09 JP JP2021559435A patent/JP7511576B2/ja active Active
- 2020-04-09 CN CN202080042521.7A patent/CN113993898B/zh active Active
- 2020-04-09 MA MA055615A patent/MA55615A/fr unknown
-
2021
- 2021-10-07 IL IL287067A patent/IL287067A/en unknown
-
2024
- 2024-01-11 JP JP2024002528A patent/JP7688175B2/ja active Active
-
2025
- 2025-05-22 JP JP2025085725A patent/JP7904951B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | The role of interleukin-17 in inflammation-related cancers | |
| Zhong et al. | A novel IL6 antibody sensitizes multiple tumor types to chemotherapy including trastuzumab-resistant tumors | |
| AU2022246477A1 (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
| EP3894013A1 (en) | Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent | |
| JP2024028805A (ja) | がん処置のための坑il-8抗体及び坑pd-1抗体を用いる組合せ治療 | |
| CN114761013A (zh) | 治疗骨髓纤维化和相关病症的方法 | |
| US20230088070A1 (en) | Use of il-1beta binding antibodies | |
| JP2015514113A (ja) | 単一特異性および二重特異性抗igf−1rおよび抗erbb3抗体の用法および用量 | |
| Schinzari et al. | Targeted therapy in advanced gastric carcinoma: the future is beginning | |
| US20250092127A1 (en) | IL-4/IL-13 Pathway Inhibitors for Enhanced Efficacy in Treating Cancer | |
| US20230101029A1 (en) | Methods of using il-33 protein in treating cancers | |
| Duong et al. | T cell Immunoglobulin and mucin domain containing protein 3 (TIM-3) inhibitors in oncology clinical trials: a review | |
| JP2024038034A (ja) | 膀胱癌の抗pd-l1抗体治療 | |
| JP2019527697A5 (cg-RX-API-DMAC7.html) | ||
| JP2020510673A (ja) | がんの治療のための低分子csf−1r阻害剤とcd40に特異的に結合するアゴニスト抗体とを含む併用療法 | |
| JP7341130B2 (ja) | 癌を治療するための組成物および治療方法 | |
| Wu et al. | Next‐Generation HER‐2 Tumor‐Targeted Delivery of the STING Agonist Immune‐Stimulating Antibody Conjugate (ISAC) Improves Anticancer Efficacy and Induces Immunological Memory | |
| US20160324962A1 (en) | Compositions and methods for treating sarcoma | |
| RU2021129250A (ru) | Человеческие антитела, связывающие ret, и способы их применения | |
| Donzelli et al. | Managing Treatment‐Emergent Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CAR‐T Cell Therapy: A Case‐Based Review of the use of Emapalumab | |
| Al-Batran et al. | Recent advances and future trends in the targeted therapy of metastatic gastric cancer | |
| EP3164154A1 (en) | Combination therapy | |
| JP2023511277A (ja) | Ccr5陽性の転移性のがんの処置のためのccr5結合剤 | |
| US20220089740A1 (en) | Tim-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer | |
| Garrido et al. | The anti-tumor activity of the 7A7 antibody, specific to murine EGFR, is independent of target expression levels in immunocompetent mice |